Breyanzi®: THE ONE with a safety profile you can count on, including 3.4% Grade ≥3 CRS events in Breyanzi trials1,2

The primary safety analysis was conducted in the full safety set (N=769), which included all patients who received a single dose of CAR-positive viable T cells.1

In both clinical trials and the real-world setting, most CRS and NT events occurred and resolved quickly.1,2

Across clinical trials of Breyanzi (N=769), 56% of patients experienced Any Grade CRS and 3.4% of patients experienced Grade ≥3 CRS. Median time to onset of CRS was 5 (range: 1-63) days; median duration was 5 (range: 1-37) days1

In pivotal clinical trails for indications approved as of June 2025 (N=702)1,2

Any Grade CRS occurred in 54% of patients. 1% of patients experienced Grade ≥3 CRS at onset.
5 median days to onset.
5 median days of duration. 98% of CRS events occurred within 2 weeks after infusion.

No Grade 5 CRS events in pivotal clinical trials2

In the real-world setting (N=877)2

Any Grade CRS occurred in 49% of patients. Grade ≥3 CRS occurred in 2.7% of patients.
4 median days to onset.
4 median days of duration. 97% of CRS events occurred within 2 weeks after infusion.

Analysis limitations: Real-world data outcomes should be interpreted with caution. Analyses not intended to be compared to controlled clinical trial data. Causality cannot be established based on real-world data. Results may not be generalizable to other disease states or cell therapy products.

CRS-related clinical trial details (N=769)1,3

  • Prophylactic systemic corticosteroids were not used in Breyanzi trials
  • CRS resolved in 99% of patients with a median duration of 5 (range: 1-37) days
  • One patient had fatal CRS and 5 patients had ongoing CRS at the time of death
  • The most common manifestations of CRS (≥10%) included fever, hypotension, chills, tachycardia, hypoxia, and headache

Cytokine release syndrome warnings and precautions1

  • CRS, including fatal or life-threatening reactions, occurred following treatment with Breyanzi
  • Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome.
  • Ensure that 2 doses of tocilizumab are available prior to infusion of BREYANZI.
  • Monitor patients daily for at least 7 days following Breyanzi infusion for signs and symptoms of CRA. Continue to monitor patients for signs or symptoms of CRS for at least 2 weeks after infusion. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteriods as indicated.
  • Counsel patients to seek immediate medical attention should signs of symptoms of CRS occur at any time

Study design2

  • Data from 5 pivotal trials included patients treated with Breyanzi across approved indications; data from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry included patients who received Breyanzi for R/R LBCL and had => 1 assessment after infusion.
  • Objectives of the study were to report CRS and NT rate and timing in patients treated with Breyanzi in pivotal clinical trials across indications or in the real-world standard of care (SoC) setting to inform safety monitoring requirements
  • Outcomes were incidence, onset, grade, and duration of CRS and NT from pivotal trials and the CIBMTR Registry

CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; CRS, cytokine release syndrome; FL, follicular lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; NT, neurologic toxicity; R/R, relapsed or refractory; SLL, small lymphocytic lymphoma.

Across clinical trials of Breyanzi (N=769), 32% of patients experienced Any Grade NT and 10% of patients experienced Grade ≥3 NT. Median time to onset for NT was 8 (range: 1-63) days; median duration was 7.5 (range: 1-119) days1

In pivotal clinical trails for indications approved as of June 2025 (N=702)1,2

Any Grade NT occurred in 31% of patients. 4.6% of patients experienced Grade ≥3 NT at onset. 
8 median days to onset. 7 median days of duration. 88% of NT events occurred within 2 weeks after infusion.

No Grade 5 NT events in pivotal clinical trials2

In the real-world setting (N=877)2

Any Grade NT occurred in 27% of patients. Grade ≥3 NT occurred in 10% of patients. 6 median days to onset. 5.5 median days of duration. 95% of NT events occurred within 2 weeks after infusion.

Analysis limitations: Real-world data outcomes should be interpreted with caution. Analyses not intended to be compared to controlled clinical trial data. Causality cannot be established based on real-world data. Results may not be generalizable to other disease states or cell therapy products.

NT-related clinical trial details (N=702)1

  • NTs resolved in 88% of cases with a median duration of 7.5 (range: 1-119) days
  • 83% of patients with NT developed CRS
  • The most common NTs (≥5%) included encephalopathy, tremor, aphasia, delirium, and headache

Neurologic toxicities warnings and precautions1

  • Neurologic toxicities that were fatal or life-threatening, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred following treatment with BREYANZI. Serious events including cerebral edema and seizures occurred with BREYANZI. Fatal and serious cases of leukoencephalopathy, some attributable to fludarabine, also occurred.
  • Monitor patients daily for at least 7 days following Breyanzi infusion for signs and symptoms of neurologic toxicities and asses for other causes of neurological symptoms. Continue to monitor patients for signs or symptoms of neurologic toxicities for at least 2 weeks after infusion and treat promptly. Manage neurologic toxicity with supportive care and/or corticosteroids as needed. Advise patients to avoid driving for at least 2 weeks following infusion.
  • Counsel patients to seek immediate medical attention should signs or symptoms of neurologic toxicity occur at any time.

Study design2

  • Data from 5 pivotal trials included patients treated with Breyanzi across approved indications; data from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry included patients who received Breyanzi for R/R LBCL and had => 1 assessment after infusion.
  • Objectives of the study were to report CRS and NT rate and timing in patients treated with Breyanzi in pivotal clinical trials across indications or in the real-world standard of care (SoC) setting to inform safety monitoring requirements
  • Outcomes were incidence, onset, grade, and duration of CRS and NT from pivotal trials and the CIBMTR Registry

CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; CRS, cytokine release syndrome; FL, follicular lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; NHL, non-Hodgkin lymphoma; NT, neurologic toxicity; R/R, relapsed or refractory; SLL, small lymphocytic lymphoma.

Breyanzi was evaluated in 3L+ CLL/SLL in TRANSCEND CLL (N=89)1

TRANSCEND CLL was an open-label, single-arm study, which evaluated 89 adult patients with R/R CLL/SLL who had received at least 2 prior lines of therapy including a BTK inhibitor and a BCL-2 inhibitor before receiving a single dose of CAR-positive viable T cells.

  • Serious adverse reactions occurred in 60% of patients. The most common nonlaboratory, serious adverse reactions (>2%) were CRS, encephalopathy, febrile neutropenia, pneumonia, hemorrhage, fever, renal failure, aphasia, abdominal pain, delirium, tumor lysis syndrome, upper respiratory tract infection, and hemophagocytic lymphohistiocytosis (IEC-HS). Fatal adverse reactions occurred in 1.1% of patients
  • The most common nonlaboratory adverse reactions (≥20%) were CRS, encephalopathy, fatigue, musculoskeletal pain, nausea, edema, diarrhea, dyspnea, headache, fever, decreased appetite, constipation, tremor, dizziness, infection with pathogen unspecified, rash, tachycardia, cough, and delirium

In clinical trials of Breyanzi (N=769)1

  • Grade ≥3 infections occurred in 12% of all patients. Infections of any grade occurred in 33% of patients

Adverse reactions in ≥10% of patients treated with Breyanzi in TRANSCEND CLL (N=89)1

Adverse reactions Any grade (%) Grade ≥3 (%)
Blood and lymphatic system disorders    
Febrile neutropenia 12 12
Cardiac disorders    
Tachycardia* 21 0
Gastrointestinal disorders    
Nausea 35 0
Diarrhea* 30 1.1
Constipation 24 0
Abdominal pain* 18 0
Vomiting 15 0
General disorders and administration site conditions    
Fatigue* 40 4.5
Endemaa 30 4.5
Fever* 27 1.1
Chills 17 1.1
Immune system disorders    
Cytokine release syndrome 83 9
Infections and infestations    
Infection with pathogen unspecified* 23 10
Upper respiratory tract infection* 19 1.1
Viral infection* 10 1.1
Metabolism and nutrition disorders    
Decreased appetite 27 4.5
Tumor lysis syndrome 11 11
Musculoskeletal and connective tissue disorders    
Musculoskeletal pain* 42 1.1
Nervous system disorders    
Encephalopahtyb 44 18
Headache* 28 1.1
Tremor 24 2.2
Dizzinessc 21 1.1
Motor dysfunctiond 14 2.2
Peripheral neuropathye 12 0
Taste disorder* 10 0
Psychiatric disorders    
Deliriumf 20 3.4
Insomnia 16 1.1
Anxiety 12 1.1
Renal and urinary disorders    
Renal failure* 15 3.4
Respiratory, thoracic, and mediastinal disorders    
Dyspnea* 27 8
Cough* 20 0
Skin and subcutaneous tissue disorders    
Rashg 23 2.2
Vascular disorders    
Hypotension* 17 0
Hemorrhageh 16 1.1
Hypertension 10 4.5

*Represents multiple related terms.1

aEdema includes ascites, face edema, hypervolemia, edema peripheral, pleural effusion, pulmonary edema, scrotal edema.   bEncephalopathy includes cognitive disorder, confusional state, disturbance in attention, encephalopathy, lethargy, memory impairment, mental status changes, somnolence.   cDizziness includes dizziness, presyncope, syncope, vertigo.   dMotor dysfunction includes asterixis, muscle spasms, muscular weakness, myoclonus.   ePeripheral neuropathy includes hyperesthesia, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral sensory neuropathy.   fDelirium includes agitation, delirium, hallucination, hallucination visual, intensive care unit delirium, irritability, restlessness.   gRash includes dermatitis contact, erythema, petechiae, rash, rash macular, rash maculo-papular, scrotal erythema, seborrheic keratosis, urticaria.   hHemorrhage includes epistaxis, hemorrhage intracranial, hematoma, hematuria, hemorrhoidal hemorrhage, intraventricular hemorrhage, lower gastrointestinal hemorrhage, traumatic hemothorax.


3L, third-line; BCL-2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CAR, chimeric antigen receptor; CLL, chronic lymphocytic leukemia; CRS, cytokine release syndrome; NT, neurologic toxicity; SLL, small lymphocytic lymphoma.

References

  1. Breyanzi [package insert]. Summit, NJ: Bristol-Myers Squibb Company; 2025.
  2. Kamdar M, Shadman M, Ahmed S, et al. Optimizing post–chimeric antigen receptor T cell monitoring: evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience. Presented at American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2025; Chicago, IL. Poster 7026.
  3. Data on file. BMS-REF-LIS-0070. Princeton, NJ: Bristol-Myers Squibb Company; 2024.
References
Important Safety Information
Indication

BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of:

  • adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Important Safety Information

WARNING: CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, AND SECONDARY HEMATOLOGICAL MALIGNANCIES

  • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab with or without corticosteroids.
  • Neurologic toxicities, including fatal or life-threatening reactions, occurred in patients receiving BREYANZI, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with BREYANZI. Provide supportive care and/or corticosteroids as needed.
  • T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI.

Cytokine Release Syndrome

Cytokine release syndrome (CRS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. In clinical trials of BREYANZI, which enrolled a total of 769 patients with non-Hodgkin lymphoma (NHL), CRS occurred in 56% of patients, including ≥ Grade 3 CRS in 3.4% of patients. The median time to onset was 5 days (range: 1 to 63 days). CRS resolved in 99% of patients with a median duration of 5 days (range: 1 to 37 days). One patient had fatal CRS and 5 patients had ongoing CRS at the time of death. The most common manifestations of CRS (≥10%) were fever, hypotension, chills, tachycardia, hypoxia, and headache.

Serious events that may be associated with CRS include cardiac arrhythmias (including atrial fibrillation and ventricular tachycardia), cardiac arrest, cardiac failure, diffuse alveolar damage, renal insufficiency, capillary leak syndrome, hypotension, hypoxia, and hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).

Ensure that 2 doses of tocilizumab are available prior to infusion of BREYANZI.

Neurologic Toxicities

Neurologic toxicities that were fatal or life-threatening, including immune effector cell-associated neurotoxicity syndrome (ICANS), occurred following treatment with BREYANZI. Serious events including cerebral edema and seizures occurred with BREYANZI. Fatal and serious cases of leukoencephalopathy, some attributable to fludarabine, also occurred.

In clinical trials of BREYANZI, CAR T cell-associated neurologic toxicities occurred in 32% of patients, including ≥ Grade 3 cases in 10% of patients. The median time to onset of neurotoxicity was 8 days (range: 1 to 63 days). Neurologic toxicities resolved in 88% of patients with a median duration of 7.5 days (range: 1 to 119 days). Of patients developing neurotoxicity, 83% also developed CRS.

The most common neurologic toxicities (≥5%) included encephalopathy, tremor, aphasia, delirium, and headache.

CRS and Neurologic Toxicities Monitoring

Monitor patients daily for at least 7 days following BREYANZI infusion for signs and symptoms of CRS and neurologic toxicities and assess for other causes of neurological symptoms. Continue to monitor patients for signs and symptoms of CRS and neurologic toxicities for at least 2 weeks after infusion and treat promptly. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated. Manage neurologic toxicity with supportive care and/or corticosteroid as needed. Advise patients to avoid driving for at least 2 weeks following infusion. Counsel patients to seek immediate medical attention should signs or symptoms of CRS or neurologic toxicity occur at any time.

Hypersensitivity Reactions

Allergic reactions may occur with the infusion of BREYANZI. Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO).

Serious Infections

Severe infections, including life-threatening or fatal infections, have occurred in patients after BREYANZI infusion. In clinical trials of BREYANZI, infections of any grade occurred in 33% of patients, with Grade 3 or higher infections occurring in 12% of all patients. Grade 3 or higher infections with an unspecified pathogen occurred in 7%, bacterial infections in 3.5%, viral infections in 2%, and fungal infections in 0.7% of patients. One patient who received 4 prior lines of therapy developed a fatal case of John Cunningham (JC) virus progressive multifocal leukoencephalopathy 4 months after treatment with BREYANZI. One patient who received 3 prior lines of therapy developed a fatal case of cryptococcal meningoencephalitis 35 days after treatment with BREYANZI.

Febrile neutropenia developed after BREYANZI infusion in 8% of patients. Febrile neutropenia may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.

Monitor patients for signs and symptoms of infection before and after BREYANZI administration and treat appropriately. Administer prophylactic antimicrobials according to standard institutional guidelines. Avoid administration of BREYANZI in patients with clinically significant, active systemic infections.

Viral reactivation: Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. In clinical trials of BREYANZI, 35 of 38 patients with a prior history of HBV were treated with concurrent antiviral suppressive therapy. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines.

Prolonged Cytopenias

Patients may exhibit cytopenias not resolved for several weeks following lymphodepleting chemotherapy and BREYANZI infusion. In clinical trials of BREYANZI, Grade 3 or higher cytopenias persisted at Day 29 following BREYANZI infusion in 35% of patients, and included thrombocytopenia in 25%, neutropenia in 22%, and anemia in 6% of patients. Monitor complete blood counts prior to and after BREYANZI administration.

Hypogammaglobulinemia

B-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 9% of patients. Hypogammaglobulinemia, either as an adverse reaction or laboratory IgG level below 500 mg/dL after infusion, was reported in 30% of patients. Monitor immunoglobulin levels after treatment with BREYANZI and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement as clinically indicated.

Live vaccines: The safety of immunization with live viral vaccines during or following BREYANZI treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during BREYANZI treatment, and until immune recovery following treatment with BREYANZI.

Secondary Malignancies

Patients treated with BREYANZI may develop secondary malignancies. T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including BREYANZI. Mature T cell malignancies, including CAR-positive tumors, may present as soon as weeks following infusion, and may include fatal outcomes. Monitor lifelong for secondary malignancies. In the event that a secondary malignancy occurs, contact Bristol-Myers Squibb at 1-888-805-4555 for reporting and to obtain instructions on collection of patient samples for testing.

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS)

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS), including fatal or life-threatening reactions, occurred following treatment with BREYANZI. Seven out of 769 (0.9%) patients with R/R NHL exposed to BREYANZI developed IEC-HS. Time to onset of IEC-HS ranged from 7 to 32 days. Of the 7 patients, 3 patients developed IEC-HS with overlapping occurrence of CRS and neurotoxicity, 2 patients developed IEC-HS with overlapping occurrence of neurotoxicity, and 1 patient developed IEC-HS with overlapping occurrence of CRS. IEC-HS was fatal in 2 of 7 patients. One patient had fatal IEC-HS and one had ongoing IEC-HS at time of death. IEC-HS is a life-threatening condition with a high mortality rate if not recognized and treated early. Treatment of IEC-HS should be administered per current practice guidelines.

Adverse Reactions

The most common adverse reaction(s) (incidence ≥30%) in:

  • CLL/SLL are CRS, encephalopathy, fatigue, musculoskeletal pain, nausea, edema, and diarrhea. The most common Grade 3-4 laboratory abnormalities include neutrophil count decrease, white blood cell decrease, hemoglobin decrease, platelet count decrease, and lymphocyte count decrease.

Please see full Prescribing Information, including Boxed WARNINGS and Medication Guide.

 

Bristol Myers Squibb logo
Legal Notice Privacy Policy Your Privacy Choices Site Map Contact Us

© 2025 Juno Therapeutics, Inc., a Bristol Myers Squibb company. All Rights Reserved.
BREYANZI is a trademark of Juno Therapeutics, Inc., a Bristol Myers Squibb company.
Cell Therapy 360 is a trademark of Celgene Corporation, a Bristol Myers Squibb company.

© 2025 Bristol Myers Squibb company.

2009-US-2500734

12/2025